Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease
View original at globenewswire.comSerina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease - First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of commo…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
By using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood
60% confidenceThe milestone-gated structure of this financing aligns capital deployment with trial progress and preserves flexibility to access additional strategic and non-dilutive funding
60% confidenceCompany remains laser-focused on generating the clinical data that will demonstrate the potential of SER-252 to transform the treatment of advanced Parkinson's disease
60% confidenceThis financing positions Serina to execute on the most value-creating milestones in the Company's history with the first patient dosed in registrational trial and a clear 505(b)(2) pathway aligned with the FDA
60% confidenceContinuous dopaminergic stimulation has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson's disease
60% confidenceThe most compelling opportunities are those that others initially overlook but that ultimately unlock significant therapeutic value
60% confidenceSER-252 has the potential to become a best-in-class therapy for the approximately 250,000 advanced Parkinson's patients in the U.S. and Europe whose symptoms remain inadequately controlled by current treatments
60% confidenceThe Company is targeting topline results from the single-ascending dose (SAD) study arm in the first half of 2027
60% confidencePreclinical studies support the potential of SER-252 to provide continuous dopaminergic stimulation without skin reactions
60% confidenceSerina expects that a blinded review of safety and tolerability data from Cohort 1 will support advancement to Cohort 2 in the third quarter of 2026
60% confidenceSerina's POZ technology has the potential to improve the safety and pharmacokinetic profile of drugs that have historically been constrained by side effects, opening the door to a portfolio of optimized medicines
60% confidenceWith recent FDA feedback confirming a clear and capital-efficient 505(b)(2) regulatory pathway for SER-252, the Company now has a well-defined route toward registration
60% confidence